Jeana Drugac
Family · Mountain Lakes, NJNPI 1508263989
Payments from drug & device makers
Across 363 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$750
- AstraZeneca$707
- Daiichi Sankyo Inc.$477
- Novartis$476
- GSK$321
- Johnson & Johnson$307
- plus $3K from 49 others
What the payments were for
- Food & beverage$6,305100%
- Education$310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,336 in reported general payments places this provider in the 95th percentile of 2,692 family providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 44 | $633,663 |
| ImbruvicaIbrutinib | 28 | $456,024 |
| CabometyxCabozantinib S-Malate | 14 | $440,627 |
| ProcritEpoetin Alfa | 114 | $330,575 |
| Darzalex FasproDaratumumab-Hyaluronidase-Fihj | 17 | $299,303 |
| NeulastaPegfilgrastim | 31 | $257,601 |
| ReblozylLuspatercept-Aamt | 18 | $240,575 |
| XtandiEnzalutamide | 13 | $185,310 |
| CalquenceAcalabrutinib Maleate | 12 | $141,061 |
| AbraxanePaclitaxel Protein-Bound | 14 | $100,077 |
| XgevaDenosumab | 14 | $43,282 |
| XareltoRivaroxaban | 44 | $35,258 |
| EliquisApixaban | 44 | $32,229 |
| Palonosetron Hcl | 16 | $1,808 |
| Anastrozole | 62 | $776 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $180 | $633,66344 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $67 | $456,02428 claims |
| Johnson & JohnsonProcrit, Xarelto | $307 | $365,833158 claims |
| AmgenNeulasta, Xgeva | $274 | $300,88345 claims |
| E.r. Squibb & Sons, L.L.C.Reblozyl | $750 | $240,57518 claims |
| Astellas Pharma US IncXtandi | $109 | $185,31013 claims |
| AstraZenecaCalquence | $707 | $141,06112 claims |
| Bristol Myers SquibbAbraxane | $48 | $100,07714 claims |
| PfizerEliquis | $81 | $32,22944 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,692 family providers in New Jersey.
Other family in Mountain Lakes
- Jennifer DemaioMorristown$412K
- Kara TrlicaCranbury$186K
- Nicole BauerParamus$161K
- Angie GarciaWest New York$161K
- China BattistaWall Township$142K
- Nancy EisenbergerVoorhees$82K
- Jennifer AbitabiloGlen Ridge$54K
- Megan FiloramoMorristown$53K
- Shawn DenningToms River$29K
- Kimberly ClementeEatontown$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.